Prednisone Taper

Phase 2Small molecule

SShilpa Grover, MD, MPH

Prednisone Taper is one of 25 small molecule programs targeting Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColitisActive, not recruiting

ColitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Colitis

#DrugCompanyPhaseTrials

Simponi

Johnson & Johnson

Approved

1 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Imuran

LLegacy Health System

Approved

1 5

Medrol

Pfizer

Phase 3

2 6

Dificlir

Merck & Co.

Phase 3

1 7

Remicade

OOrganon and Co

Phase 3

5 8

Stelara

Johnson & Johnson

Phase 3

—9

Bismuth Subsalicylate

Biogen

Approved

1 10

Entyvio

Takeda

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Colitis

NCT06841705

Clinical

Trials by Indication[1]

Colitis1 trial

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Recruiting·SShilpa Grover, MD, MPH·Phase 2·NCT06841705·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prednisone Taper. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prednisone Taper compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prednisone Taper. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shilpa Grover, MD, MPH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShilpa Grover, MD, MPH

Prednisone Taper

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Colitis1 trial

References

Drug Info

Quick Facts

Related News